Summary
Founded in 2010, AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. The company’s products are oriented to non-invasive early cancer detection, avoiding the complications of existing invasive procedures, as tumor biopsies in colon, lung and pancreatic cancer.
The application of Advanced Data Analytical tools in healthcare has a lot of positive and also life-saving potential. When speaking about data, we are referring to the vast quantities of information created in digitization of medical documents, and that could be consolidated and analyzed applying specific technologies. Aligned with our mission, AMADIX continues to go further, not only working at a molecular level but also exploring possibilities that clinical records and patient data offer (particular conditions, lifestyle, living area…). We are registering, processing and analyzing data through the latest Artificial Intelligence (AI) and Advanced Data Analytical Tools, in order to identify new risk factors, to develop predictive models which will help us anticipate hidden underlying cancer risk factors, treat patients in time and help improve the quality of life and survival of cancer patients. So, as an overview, the objective of AMX DATA is identifying risk factors in colon, lung and pancreatic cancer based on medical history, individual habits and image analysis to incorporate new risk cancer factors - in combination with our blood test gene signature - into our algorithms using Big Data tools and Artificial Intelligence.
The development of this disruptive project requires the recruitment of an Innovation Associate with a multidisciplinary set of skills combining expertise and knowledge in cancer diagnostics and data analysis tools.
The application of Advanced Data Analytical tools in healthcare has a lot of positive and also life-saving potential. When speaking about data, we are referring to the vast quantities of information created in digitization of medical documents, and that could be consolidated and analyzed applying specific technologies. Aligned with our mission, AMADIX continues to go further, not only working at a molecular level but also exploring possibilities that clinical records and patient data offer (particular conditions, lifestyle, living area…). We are registering, processing and analyzing data through the latest Artificial Intelligence (AI) and Advanced Data Analytical Tools, in order to identify new risk factors, to develop predictive models which will help us anticipate hidden underlying cancer risk factors, treat patients in time and help improve the quality of life and survival of cancer patients. So, as an overview, the objective of AMX DATA is identifying risk factors in colon, lung and pancreatic cancer based on medical history, individual habits and image analysis to incorporate new risk cancer factors - in combination with our blood test gene signature - into our algorithms using Big Data tools and Artificial Intelligence.
The development of this disruptive project requires the recruitment of an Innovation Associate with a multidisciplinary set of skills combining expertise and knowledge in cancer diagnostics and data analysis tools.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/957099 |
| Start date: | 01-10-2020 |
| End date: | 31-12-2021 |
| Total budget - Public funding: | - 129 500,00 Euro |
Cordis data
Original description
Founded in 2010, AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. The company’s products are oriented to non-invasive early cancer detection, avoiding the complications of existing invasive procedures, as tumor biopsies in colon, lung and pancreatic cancer.The application of Advanced Data Analytical tools in healthcare has a lot of positive and also life-saving potential. When speaking about data, we are referring to the vast quantities of information created in digitization of medical documents, and that could be consolidated and analyzed applying specific technologies. Aligned with our mission, AMADIX continues to go further, not only working at a molecular level but also exploring possibilities that clinical records and patient data offer (particular conditions, lifestyle, living area…). We are registering, processing and analyzing data through the latest Artificial Intelligence (AI) and Advanced Data Analytical Tools, in order to identify new risk factors, to develop predictive models which will help us anticipate hidden underlying cancer risk factors, treat patients in time and help improve the quality of life and survival of cancer patients. So, as an overview, the objective of AMX DATA is identifying risk factors in colon, lung and pancreatic cancer based on medical history, individual habits and image analysis to incorporate new risk cancer factors - in combination with our blood test gene signature - into our algorithms using Big Data tools and Artificial Intelligence.
The development of this disruptive project requires the recruitment of an Innovation Associate with a multidisciplinary set of skills combining expertise and knowledge in cancer diagnostics and data analysis tools.
Status
CLOSEDCall topic
INNOSUP-02-2019-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
